Para-phenylenediamine and allergic sensitization:risk modification by N-acetyltransferase 1 and 2 genotypes by Bloemeke, B. et al.
  
 University of Groningen
Para-phenylenediamine and allergic sensitization
Bloemeke, B.; Brans, R.; Coenraads, P. -J.; Dickel, H.; Bruckner, T.; Hein, D. W.; Heesen, M.;
Merk, H. -F.; Kawakubo, Y.; Blomeke, B.
Published in:
BRITISH JOURNAL OF DERMATOLOGY
DOI:
10.1111/j.1365-2133.2009.09352.x
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2009
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Bloemeke, B., Brans, R., Coenraads, P. -J., Dickel, H., Bruckner, T., Hein, D. W., ... Blomeke, B. (2009).
Para-phenylenediamine and allergic sensitization: risk modification by N-acetyltransferase 1 and 2
genotypes. BRITISH JOURNAL OF DERMATOLOGY, 161(5), 1130-1135. https://doi.org/10.1111/j.1365-
2133.2009.09352.x
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
CONTACT DERMATITIS AND ALLERGY BJD British Journal of Dermatology
Para-phenylenediamine and allergic sensitization: risk
modiﬁcation by N-acetyltransferase 1 and 2 genotypes
B. Blo¨meke, R. Brans,* P.-J. Coenraads, H. Dickel, T. Bruckner,§ D.W. Hein,– M. Heesen,** H.-F. Merk*
and Y. Kawakubo
Department of Environmental Toxicology, University Trier, Am Wissenschaftspark 25–27, 54296 Trier, Germany
*Department of Dermatology and Allergology, University Hospital of the RWTH Aachen, Pauwelsstr. 30, 52057 Aachen, Germany
Department of Dermatology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, the Netherlands
Department of Dermatology and Allergology, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
§Department of Social Medicine, Occupational and Environmental Dermatology, University Hospital of Heidelberg, 69115 Heidelberg, Germany
–Department of Pharmacology and Toxicology and James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY, U.S.A.
**Department of Anaesthesia, Klinikum Bamberg, Burger Str. 80, 96049 Bamberg, Germany







allergic contact dermatitis, metabolism,




With the exception of D.W.H., none declared.




Background Para-phenylenediamine (PPD) is a common contact sensitizer causing
allergic contact dermatitis, a major skin problem. As PPD may need activation to
become immunogenic, the balance between activation and ⁄or detoxification pro-
cesses may influence an individual’s susceptibility. PPD is acetylated and the
metabolites do not activate dendritic-like cells and T cells of PPD-sensitized
individuals.
Objectives To investigate whether PPD can be acetylated in vitro by the two N-acetyl-
transferases 1 (NAT1) and 2 (NAT2). Based on the assumption that N-acetylation
by NAT1 or NAT2 is a detoxification reaction with respect to sensitization, we
examined whether NAT1 and NAT2 genotypes are different between PPD-
sensitized individuals and matched controls.
Methods Genotyping for NAT1 and NAT2 polymorphisms was performed in 147
PPD-sensitized individuals and 200 age- and gender-matched controls.
Results Both PPD and monoacetyl-PPD were N-acetylated in vitro by recombinant
human NAT1 and to a lesser extent by NAT2. Genotyping for NAT1*3, NAT1*4,
NAT1*10, NAT1*11 and NAT1*14 showed that genotypes containing the rapid
acetylator NAT1*10 allele were under-represented in PPD-sensitized cases
(adjusted odds ratio 0Æ72, 95% confidence interval 0Æ45–1Æ16). For NAT2,
NAT2*4, NAT2*5AB, NAT2*5C, NAT2*6A and NAT2*7B alleles were genotyped.
Individuals homozygous for the rapid acetylator allele NAT2*4 were under-repre-
sented in cases compared with controls (4Æ3% vs. 9Æ4%), but this trend was not
significant.
Conclusions With respect to data indicating that NAT1 but not NAT2 is present in
human skin, we conclude that NAT1 genotypes containing the rapid acetyl-
ator NAT1*10 allele are potentially associated with reduced susceptibility to PPD
sensitization.
Para-phenylenediamine (PPD) is a widely used precursor in
many processes including hair dye formulations.1,2 Sensitiza-
tion to PPD causes allergic contact dermatitis (ACD), a com-
mon skin problem.3,4 In addition, ACD due to PPD-containing
skin paints (temporary tattoos) is increasingly reported.5,6 Sen-
sitization to PPD in a 10-year period was diagnosed in 4% of
patients tested.7 In the general population this corresponds to
a 10-year prevalence of 0Æ96% based on recently published
data.8
Despite the many years in which PPD has been used and
allergy to PPD has been recognized, the underlying
mechanisms of sensitization have remained elusive.9 Initially,
PPD was considered as prohapten and the auto-oxidation
product Bandrowski’s base [BB, N,N’-bis(4-aminophenyl)-2,
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5-diamino-1,4-quinone-diimine] as the real immunogen in
PPD allergy.10 However, more recent studies focusing on
activation of human dendritic cells suggest that both PPD itself
and immediately formed derivatives are involved in sensitiza-
tion.11 In addition, studies on human lymphocytes from aller-
gic patients support the role of PPD during elicitation,12,13
and data from nonallergic individuals suggest that PPD or a
related derivative other than BB is involved in the elicitation
of ACD.14
Under exposure conditions provided by hair dyeing with
PPD, 1Æ3% of the applied dose is considered as available for
metabolism in the epidermis and dermis.15–17 Transformation
of PPD by N-acetyltransferase 1 (NAT1) has been reported by
us for keratinocytes and in vitro-generated monocyte-derived
dendritic cells.18,19 When N-acetylated PPD metabolites,
namely monoacetyl-PPD (MAPPD) and diacetyl-PPD (DAPPD),
were analysed for their capacity to mature human dendritic
cells or to induce sensitization in the local lymph node
assay,20 no response was observed. In addition, MAPPD and
DAPPD did not reactivate T cells from PPD-allergic patients in
vitro21 or in vivo.22 Furthermore, using primary human kerati-
nocytes we also demonstrated that the acetylated compounds
are not substrates for the formation of BB,18 thereby probably
reducing the amount of immunogens available for sensitiza-
tion and allergic reactions.
These data indicate that NAT1 acetylation represents a
detoxification pathway, and we hypothesized that the N-acety-
lation status may influence an individual’s susceptibility for
reactions to PPD. Arylamine N-acetyltransferases 1 and 2
(NAT1, NAT2) are present in different body tissues.23 NAT2
is found mainly in the liver and the gastrointestinal tract,24
whereas NAT1 is present in various organs25 including skin.18
Interindividual genetic variations have been shown to cause
differences in NAT1 and NAT2 protein levels and are associ-
ated with a slow or rapid N-acetylation activity.24,26–28
NAT1*10 has been associated with high N-acetylation
activity,29,30 whereas haplotypes such as NAT1*1131 and
NAT1*1432 are associated with a low enzyme activity. NAT1
and NAT2 have been studied as susceptibility factors for
various diseases, based on the observation that both enzymes
are involved in the biotransformation of arylamines.33 Associa-
tions between the acetylator status and cancers including
bladder cancer34–36 and colon cancer37,38 are known.
The association between the acetylator status and skin sensi-
tization to small chemicals has hardly been addressed. An
earlier small study found a higher proportion of the rapid
acetylator genotype NAT1*1039 among polysensitized cases. An
association with NAT2 acetylator genotypes was additionally
reported in about 70 PPD-sensitized cases.40 These conflicting
data indicate that further exploration of the importance of
N-acetyltransferases for allergic diseases is necessary. In the
present study, we investigated if PPD is indeed acetylated by
both known N-acetyltransferases NAT1 and NAT2, using
recombinant enzymes. Furthermore, the influence of the indi-
vidual NAT1 and NAT2 genotypes on an individual’s suscepti-
bility to sensitization by PPD was assessed by studying the
frequencies of the most common single nucleotide polymor-
phisms in NAT1 and NAT2 among PPD-sensitized individuals
compared with age- and gender-matched controls.
Materials and methods
N-acetylation of para-phenylenediamine (PPD) and
monoacetyl-PPD by human NAT1 and NAT2 enzymes
recombinantly expressed in yeast
Human NAT1 (NAT1 4) and NAT2 (NAT2 4) enzymes were
recombinantly expressed in yeast as previously described.32,41
N-acetyltransferase assays were conducted in triplicate as
previously described.18 Yeast lysates were incubated
with 2 mmol L)1 PPD (Sigma, St Louis, MO, U.S.A.) or
0Æ8 mmol L)1 MAPPD (Aldrich Chemical Company, Inc., Mil-
waukee, WI, U.S.A.) in the presence of 1 mmol L)1 acetyl
coenzyme A (Sigma). The acetylated products were separated
from reactants and quantified by high-performance liquid
chromatography. Controls substituted buffer for acetyl coen-
zyme A. Total protein in cell lysates was measured by the
Bradford assay using the Bio-Rad protein assay reagent (Bio-
Rad, Hercules, CA, U.S.A.).
Subjects for genotyping
For genotyping, 147 unrelated caucasian individuals with a
history of ACD and sensitization to PPD based on a positive
patch-test reaction (1+ to 3+, according to the International
Contact Dermatitis Research Group classification) at 48, 72 or
96 h after application and 200 unrelated caucasian age- and
gender-matched control individuals with no known history
of sensitization to PPD or ACD were recruited in Germany
(Aachen area) and in the Netherlands (Groningen area)
between 1997 and 2003. All subjects gave written informed
consent and donated blood. The study was approved by the
local ethic committee.
Genotyping for NAT1 and NAT2
Genomic DNA was extracted from whole blood or serum as
described before.42 The NAT1 haplotypes *3, *4, *10, *11 and
*14 were detected by polymerase chain reaction and restric-
tion fragment length polymorphism (PCR-RFLP) exactly as
published.29 Polymorphisms in NAT2 including NAT2 haplo-
types *4, *5AB, *5C, *6A and *7B were identified as
described.43 Duplicate quality-control samples (10%) showed
100% agreement for all assays.
Statistical analysis
Expected genotype frequencies were calculated by the Hardy–
Weinberg equation from the allelic frequencies. The P-values
obtained by Fisher’s two-sided exact test were used to test for
associations between contact sensitization and NAT1 and NAT2
polymorphisms. Crude odds ratios (ORs), ORs adjusted for
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gender and age and 95% confidence intervals (CIs) were cal-
culated from the ratio of variant vs. common genotypes in
cases and controls, or other strata, respectively. All tests were
analysed using the SAS program (SAS Institute, Inc., Cary, NC,
U.S.A.).
Results
N-acetylation of para-phenylenediamine (PPD) and
monoacetyl-PPD by recombinant NAT1 and NAT2
PPD and MAPPD were both N-acetylated in vitro by both
recombinant human NAT1 and NAT2 enzymes. The results
are summarized in Table 1.
Genotyping for NAT1 and NAT2
We genotyped PPD-allergic cases and controls for the most
common genetic polymorphisms in the genes encoding NAT1
and NAT2, assuming that N-acetylation status may be a sus-
ceptibility factor for sensitization to PPD based on very recent-
ly reported experimental results.20,22 Successful genotyping
was achieved for 147 cases (62% women; median age
44 years, range 11–96) and 200 age- and gender-matched
controls using PCR-RFLP for the most common NAT1 haplo-
types. The percentages reported here for controls (see Table 2)
are in complete agreement with frequencies published for
mid-Europeans.31 All genotypes were in Hardy–Weinberg
equilibrium, and expected frequencies did not differ signifi-
cantly from the observed distribution. Most common was the
NAT1*4 ⁄*4 genotype, which was found in 55Æ1% of cases and
51Æ0% of controls. Carriers of slow NAT1 alleles such as
NAT1*11 and NAT1*14 were more frequent in cases. However,
due to the rarity of these alleles significant differences in their
distribution between cases and controls could not be detected.
Genotypes containing the rapid NAT1*10 allele were less com-
mon in cases than in controls (30Æ6% vs. 38Æ5%, see Table 3).
The resulting decreased risk for genotypes containing NAT1*10
was almost significant (95% CI 0Æ46–1Æ18), pointing towards
a reduced sensitization risk conferred by normal or enhanced
acetylation. Because age and gender are unlikely to be associ-
ated with NAT1 genotype, the age- and gender-adjusted OR
was similar.
With regard to the NAT2 polymorphisms, we genotyped
NAT2*4, NAT2*5AB, NAT2*5C, NAT2*6A and NAT2*7B success-
fully in 138 cases and 192 controls of the above-mentioned
samples. Again, individuals homozygous for the rapid acetyla-
tor allele NAT2*4 were less frequent in cases compared with
controls (4Æ3% vs. 9Æ4%, see Table 4). As summarized in
Table 5, PPD cases consisted of 53Æ6% slow NAT2 acetylation
genotypes, whereas 51Æ0% of the controls were carriers of this
trait (OR 2Æ27, 95% CI 0Æ86–5Æ99).
Discussion
Knowledge of pharmacokinetics and metabolism following
dermal exposure are key requirements for the risk assessment
of substances that come into contact with human skin. Such
results may then provide further clues for the assessment of
the individual susceptibility. Previous studies indicate that PPD
can stimulate dendritic cell maturation under various condi-
tions11,44,45 and also lymphocyte proliferation.12,14
Recently, some investigators confirmed our findings that
PPD is acetylated in human skin and reported that acetylation
of PPD can also be performed by human hepatocytes.17,46 In
order to elucidate these processes further, we first studied if
PPD is indeed a substrate for human NAT1 and NAT2 using
recombinant enzymes derived from a yeast expression system.
We demonstrated that both NAT1 and NAT2 are able to
N-acetylate PPD and MAPPD.
Variations in NAT1 and NAT2 genes are associated with slow
or rapid N-acetylation activity24,26–28 and may confer interin-
dividual differences in disease susceptibility. We found a
decreased risk for sensitization to PPD for individuals carrying
the rapid acetylator haplotype NAT1*10. The decreased risk for
the NAT1*10 genotypes was almost significant (95% CI 0Æ45–
1Æ16). Similarly, we found a lower percentage of individuals
homozygous for the rapid acetylator allele NAT2*4 among
cases compared with controls. Because only NAT1 enzyme
activity has been found in skin cells, it is likely that PPD is
predominantly acetylated by NAT1 in human skin. Thus, it
is appropriate to hypothesize that NAT1 rather than NAT2
Table 1 N-acetylation of para-phenylenediamine (PPD) and
monoacetyl-PPD (MAPPD) by N-acetyltransferase 1 (NAT1) 4 and





NAT1 4 21Æ0 ± 0Æ9 23Æ9 ± 0Æ375
NAT2 4 0Æ456 ± 0Æ012 0Æ502 ± 0Æ012
Values represent mean ± SEM for three individual determina-
tions of N-acetyltransferase activity.
Table 2 N-acetyltransferase 1 (NAT1) genotypes in para-





(n = 147), n (%)
Controls
(n = 200), n (%)
*4 ⁄*4 81 (55Æ1) 102 (51Æ0)
*4 ⁄*10 39 (26Æ5) 71 (35Æ5)
*10 ⁄*10 6 (4Æ1) 6 (3Æ0)
*4 ⁄*3 8 (5Æ4) 9 (4Æ5)
*4 ⁄*11 7 (4Æ8) 4 (2Æ0)
*4 ⁄*14 3 (2Æ0) 3 (1Æ5)
*3 ⁄*3 1 (0Æ7) 2 (1Æ0)
*11 ⁄*11 0 2 (1Æ0)
*14 ⁄*14 1 (0Æ7) 1 (0Æ5)
*3 ⁄*14 1 (0Æ7) 0
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genotype would be important in sensitization and ACD to
PPD. Our data indicate that a fast N-acetylation activity may
reduce disease susceptibility, which is in accordance with new
data from our group22 and others demonstrating that acetyla-
tion of PPD in skin is a detoxification mechanism potentially
reducing its ability to cause sensitization and ACD.20
Although experimental data clearly support that N-acetyla-
tion of PPD is a detoxification reaction, a surprisingly low
association between the NAT1 genotypes and PPD allergy was
observed in this study and by others.39,40 The first mentioned
small study of 88 cases and 123 controls reported a borderline
(95% CI 1Æ06–75Æ6) increased risk for NAT1*10 ⁄*10 carriers.
Nevertheless, the decreased frequency of NAT1*10 allele
observed among cases in the present study is consistent with a
detoxification role by NAT1 expressed in human skin.
For NAT2 genotypes, this study found no statistically signifi-
cant differences between cases and controls while the above-
mentioned studies did find an increased proportion of rapid
acetylator genotypes among cases.39,40 Because PPD is pre-
ferentially acetylated by NAT1, the associations with the NAT2
genotypes may account for differences in case definitions, e.g.
PPD-sensitized vs. polysensitized cases. On the other hand, at
present it cannot be excluded that independent factors also
contribute to susceptibility and may dominate under certain
circumstances. Previously, we reported an association between
the )308G ⁄A polymorphism in the promoter of the gene cod-
ing for tumour necrosis factor-a and sensitization to PPD.
Table 4 N-acetyltransferase 2 (NAT2) genotypes in








*4 ⁄*4 (Sum fast acetylators) 6 (4Æ3) 18 (9Æ4)
Sum intermediate acetylators 58 (42Æ0) 76 (39Æ6)
*4 ⁄*5AB 29 (21Æ0) 49 (25Æ5)
*4 ⁄*5C 4 (2Æ9) 2 (1Æ0)
*4 ⁄*6A 25 (18Æ1) 22 (11Æ5)
*4 ⁄*7B 0 3 (1Æ6)
Sum slow acetylators 74 (53Æ6) 98 (51Æ0)
*5AB ⁄*5AB 29 (21Æ0) 26 (13Æ5)
*5AB ⁄*5C 2 (1Æ5) 10 (5Æ2)
*5AB ⁄*6A 17 (12Æ3) 39 (20Æ3)
*5AB ⁄*7B 2 (1Æ4) 5 (2Æ6)
*5C ⁄*5C 0 1 (0Æ5)
*5C ⁄*6A 10 (7Æ2) 5 (2Æ6)
*6A ⁄*6A 14 (10Æ1) 10 (5Æ2)
*6A ⁄*7B 0 2 (1Æ0)








n (%) Crude OR (95% CI)
Fisher’s









58 (42Æ0) 76 (39Æ6) 2Æ35 (0Æ88–6Æ31) 0Æ114 2Æ30 (0Æ85–6Æ21) 0Æ101
Sum slow
acetylators
74 (53Æ6) 98 (51Æ0) 2Æ27 (0Æ86–5Æ99) 0Æ121 2Æ21 (0Æ83–5Æ86) 0Æ113
CI, confidence interval. aTwo-sided Fisher’s exact test. bAdjusted for gender and age. cMaximum likelihood estimates were calculated by the
Wald statistic compared against a v2 distribution.








n (%) Crude OR (95% CI)
Fisher’s





*4 ⁄*4 81 (55Æ1) 102 (51Æ0) 1Æ0
*4 ⁄*10 39 (26Æ5) 71 (35Æ5) 0Æ69 (0Æ43–1Æ13) 0Æ143 0Æ67 (0Æ41–1Æ10) 0Æ110
*10 ⁄*10 6 (4Æ1) 6 (3Æ0) 1Æ26 (0Æ39–4Æ05) 0Æ769 1Æ29 (0Æ39–4Æ20) 0Æ677
*4 ⁄*10 + *10 ⁄*10 45 (30Æ6) 77 (38Æ5) 0Æ74 (0Æ46–1Æ18) 0Æ235 0Æ72 (0Æ45–1Æ16) 0Æ172
CI, confidence interval. aTwo-sided Fisher’s exact test. bAdjusted for gender and age. cMaximum likelihood estimates were calculated by the
Wald statistic compared against a v2 distribution.
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Although several groups including ours clearly demonstrated
that human skin cytosols, cultured keratinocytes, monocyte-
derived dendritic cells, hepatocytes and leucocytes (unpub-
lished data) acetylate PPD ex vivo,17–19 it may not be a
dominant risk factor in vivo.
During the hair dyeing process and through tattooing, only
small amounts of PPD are applied to the skin. PPD needs to
cross the stratum corneum to reach the target cells, and the
absorbed amounts may not be sufficient for efficient acetyla-
tion. This is in accordance with our estimated apparent Km val-
ues which were quite high in keratinocytes.18 Furthermore, it
has been demonstrated that apart from the genetically con-
trolled interindividual variations in NAT1 activity, also reactive
oxidative stress (ROS) and cellular redox status may regulate
NAT1 enzyme activity.47–49 Generation of ROS by PPD is dis-
cussed,50,51 and it should be mentioned that permanent hair
dyes are applied in the presence of H2O2, physiological con-
centrations of which can reversibly inactivate NAT1 in vitro.47
In summary, our results show that PPD and MAPPD are
acetylated by both human NAT1 and NAT2 and that the fast
acetylator NAT1 genotypes are somewhat less frequent in PPD-
sensitized cases. This is in agreement with experimental data
indicating that N-acetylation of PPD is a detoxification process
with regard to sensitization. With respect to previous data
indicating that NAT1 but not NAT2 is present in human skin
we conclude that the rapid acetylator genotypes containing the
NAT1*10 allele are potentially associated with reduced suscep-
tibility to PPD sensitization.
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